Novel Point-of-Care Bioassay Methods and Instrumentation for Hepatocellular Carcinoma Diagnosis and Patient Monitoring

PI

Daniel Laser, Ph.D., wave80 Biosciences, Inc.

Co-PI

Catherine Klapperich, Ph.D., Boston University


This study focuses on new enclosed-cartridge-format assay methods and instrumentation for measurement of hepatocellular carcinoma (HCC) biomarkers. The program leverages a recently developed point-of-care molecular diagnostics assay platform, the EOSCAPE system, which uses singlet oxygen-catalyzed light emission and advanced assay cartridge technology to run sophisticated assays with turnaround times below 60 minutes.  A new EOSCAPE cartridge is engineered to detect four proteins which, alone and in combination, are increasingly important in clinical management of patients at high risk for HCC and which require point-of-care measurement to facilitate timely clinical decision making.  Prototype cartridges running the new assay will be tested in a clinical environment to assess performance incorporation into clinical workflow.